Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the results of several research studies that further support the safety and efficacy of the UroLift® System for men living with enlarged prostate, or benign prostatic hyperplasia (BPH), including among those who have a wide range of prostate sizes and/or a median lobe obstruction.
July 1, 2022
· 6 min read